Premium
Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma
Author(s) -
Erem Cihangir,
Kocak Mustafa,
Nuhoglu İrfan,
Yılmaz Mustafa,
Ucuncu Ozge
Publication year - 2010
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2009.03752.x
Subject(s) - medicine , prolactinoma , endocrinology , fibrinolysis , tissue factor pathway inhibitor , partial thromboplastin time , coagulation , antithrombin , fibrinogen , plasminogen activator , hemostasis , prothrombin time , plasminogen activator inhibitor 1 , tissue factor , prolactin , hormone , heparin
Summary Objective Although the strong association between hyperprolactinaemia and platelet aggregation is well recognized, there are no studies on changes in coagulation and fibrinolytic status in patients with prolactinoma. To our knowledge, tissue plasminogen activator inhibitor‐1 (PAI‐1), plasma tissue factor pathway inhibitor (TFPI) and thrombin‐activatable fibrinolysis inhibitor (TAFI) levels in these patients have not been investigated. Therefore, the main purpose of this study was to evaluate the markers of endogenous coagulation/fibrinolysis, including TFPI and TAFI, and to investigate the relationships between prolactin (PRL) and these haemostatic parameters and serum lipid profile in patients with prolactinoma. Research methods and procedures Twenty‐two patients with untreated, newly diagnosed prolactinoma and 20 age‐matched healthy controls were included in the study. Platelet count, mean platelet volume, prothrombin time, activated partial thromboplastin time, fibrinogen, factors V, VII, VIII, IX and X activities, von Willebrand factor, antithrombin III (AT‐III), protein C, protein S, tissue plasminogen activator (t‐PA), PAI‐1, TFPI and TAFI, as well as common lipid variables, were measured. The relationships between serum PRL and these haemostatic parameters were evaluated. Results Compared with the control subjects, total cholesterol, low density lipoprotein cholesterol, apolipoprotein B, platelet count, fibrinogen, AT‐III, PAI‐1 and PAI‐1/t‐PA ratio were significantly increased in patients with prolactinoma ( P < 0·0001, P < 0·001, P < 0·05, P < 0·05, P < 0·0001, P < 0·05, P < 0·0001 and P < 0·0001, respectively), whereas TFPI levels were significantly decreased ( P < 0·01). Plasma TAFI Ag levels were not significantly different in patients with prolactinoma compared with the controls. In patients with prolactinoma, serum PRL was positively correlated with plasma FVII levels and apo B ( r : 0·679, P < 0·05; r : 0·548, P < 0·05, respectively). Conclusion We found some important differences in the haemostatic parameters between the patients with prolactinoma and healthy controls. Increased platelet count, fibrinogen, PAI‐1 and decreased TFPI in patients with prolactinoma may represent a potential hypercoagulable and hypofibrinolytic state, which might augment the risk for atherosclerotic and atherothrombotic complications. Thus, disturbances of the haemostatic system and dyslipidaemia may lead to the excess mortality in patients with prolactinoma.